Pilotto Alberto, Franceschi Marilisa, Leandro Gioacchino, Scarcelli Carlo, D'Ambrosio Luigi Piero, Paris Francesco, Annese Vito, Seripa Davide, Andriulli Angelo, Di Mario Francesco
Geriatric Unit, IRCCS, Casa Sollievo della Sofferenza, Viale Cappuccini, 71013, San Giovanni Rotondo (FG), Italy.
World J Gastroenterol. 2007 Sep 7;13(33):4467-72. doi: 10.3748/wjg.v13.i33.4467.
To compare efficacy and tolerability of four proton pump inhibitors (PPIs) commonly used in the short-term therapy of esophagitis in elderly patients.
A total of 320 patients over 65 years with endoscopically diagnosed esophagitis were randomly assigned to one of the following treatments for 8 wk: (1) omeprazole 20 mg/d; (2) lansoprazole 30 mg/d; (3) pantoprazole 40 mg/d, or (4) rabeprazole 20 mg/d. Major symptoms, compliance, and adverse events were recorded. After 8 wk, endoscopy and clinical evaluation were repeated.
Per protocol and intention to treat healing rates of esophagitis were: omeprazole = 81.0% and 75.0%, lansoprazole = 90.7% (P = 0.143 vs omeprazole) and 85.0%, pantoprazole = 93.5% (P = 0.04 vs omeprazole) and 90.0% (P = 0.02 vs omeprazole), rabeprazole = 94.6% (P = 0.02 vs omeprazole) and 88.8% (P = 0.04 vs omeprazole). Dividing patients according to the grades of esophagitis, omeprazole was significantly less effective than the three other PPIs in healing grade 1 esophagitis (healing rates: 81.8% vs 100%, 100% and 100%, respectively, P = 0.012). Pantoprazole and rabeprazole (100%) were more effective vs omeprazole (89.6%, P = 0.0001) and lansoprazole (82.4%, P = 0.0001) in decreasing heartburn. Pantoprazole and rabeprazole (92.2% and 90.1%, respectively) were also more effective vs lansoprazole (75.0%, P < 0.05) in decreasing acid regurgitation. Finally, pantoprazole and rabeprazole (95.2% and 100%) were also more effective vs lansoprazole (82.6%, P < 0.05) in decreasing epigastric pain.
In elderly patients, pantoprazole and rabeprazole were significantly more effective than omeprazole in healing esophagitis and than omeprazole or lansoprazole in improving symptoms. H pylori infection did not influence the healing rates of esophagitis after a short-term treatment with PPI.
比较四种常用于老年食管炎患者短期治疗的质子泵抑制剂(PPI)的疗效和耐受性。
共有320例65岁以上经内镜诊断为食管炎的患者被随机分配至以下治疗组之一,治疗8周:(1)奥美拉唑20mg/d;(2)兰索拉唑30mg/d;(3)泮托拉唑40mg/d,或(4)雷贝拉唑20mg/d。记录主要症状、依从性和不良事件。8周后,重复进行内镜检查和临床评估。
按照方案分析和意向性分析,食管炎的愈合率分别为:奥美拉唑=81.0%和75.0%,兰索拉唑=90.7%(与奥美拉唑相比,P=0.143)和85.0%,泮托拉唑=93.5%(与奥美拉唑相比,P=0.04)和90.0%(与奥美拉唑相比,P=0.02),雷贝拉唑=94.6%(与奥美拉唑相比,P=0.02)和88.8%(与奥美拉唑相比,P=0.04)。根据食管炎的分级对患者进行分组,在愈合1级食管炎方面,奥美拉唑的疗效显著低于其他三种PPI(愈合率分别为:81.8% vs 100%、100%和100%,P=0.012)。在减轻烧心方面,泮托拉唑和雷贝拉唑(100%)比奥美拉唑(89.6%,P=0.0001)和兰索拉唑(82.4%,P=0.0001)更有效。在减轻反酸方面,泮托拉唑和雷贝拉唑(分别为92.2%和90.1%)也比兰索拉唑(75.0%,P<0.05)更有效。最后,在减轻上腹部疼痛方面,泮托拉唑和雷贝拉唑(95.2%和100%)也比兰索拉唑(82.6%,P<0.05)更有效。
在老年患者中,泮托拉唑和雷贝拉唑在愈合食管炎方面比奥美拉唑显著更有效,在改善症状方面比奥美拉唑或兰索拉唑更有效。幽门螺杆菌感染不影响PPI短期治疗后食管炎的愈合率。